Phebra
Pharmaceutical group Phebra ('Company') today announced the launch of Laceraine®, its novel topical anaesthetic gel for open lacerations - developed and manufactured in Australia.
Laceraine®, a combination of lidocaine, tetracaine and adrenaline, will support clinicians working in hospital emergency departments ('ED'), general practice ('GP'), urgent care clinics and other frontline health settings across the community.
As an innovative gel formulation, Laceraine® provides localised anaesthesia for superficial open lacerations, where well‑tolerated pain relief is essential for wound cleaning and closure in patients, particularly children.
Phebra's Chief Executive Officer (CEO), Andre Vlok, said the development of Laceraine® demonstrates the Company's long‑standing commitment to strengthening Australia's sovereign capability in essential medicines.
"We're extremely proud to be adding Laceraine® to Phebra's portfolio of Australian-made medicines to address an unmet need for healthcare professionals and their patients," Mr. Vlok said.
Laceraine® was conceived and developed by Phebra's Co-Founder, the late Dr Mal Eutick and is manufactured in Lane Cove West, Sydney. It's Australia's only registered anaesthetic gel for open lacerations and was developed with support from Australian clinicians.
"Laceraine® delivers multiple benefits - it's less painful, it reduces bleeding, treatment time in the emergencydepartment and the risk of needlestick injuries for healthcare professionals." Mr. Vlok added.
Laceraine® is now available through Phebra's national distribution network.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).
